AstraZeneca Pharma India Ltd receives permission from CDSCO for Durvalumab Solution

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml (Brand name: Imfinzi) for an additional indication.

Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).

The receipt of this permission paves way for the marketing of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml (Brand name: Imfinzi) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 8898.25 as compared to the previous close of Rs. 8871.70. The total number of shares traded during the day was 193 in over 87 trades.

The stock hit an intraday high of Rs. 8929.00 and intraday low of 8866.00. The net turnover during the day was Rs. 1719117.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 Pharmaceuticals Permission CDSCO DurvalumabSolution